- Home
- IONR vs KOD Comparison
IONR vs KOD Comparison
Compare IONR & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- KOD
- Stock Information
- Founded
- IONR 2001
- KOD 2009
- Country
- IONR Australia
- KOD United States
- Employees
- IONR N/A
- KOD 109
- Industry
- IONR
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IONR
- KOD Health Care
- Exchange
- IONR Nasdaq
- KOD Nasdaq
- Market Cap
- IONR 262.0M
- KOD 259.6M
- IPO Year
- IONR N/A
- KOD 2018
- Fundamental
- Price
- IONR $3.55
- KOD $3.96
- Analyst Decision
- IONR
- KOD Hold
- Analyst Count
- IONR 0
- KOD 3
- Target Price
- IONR N/A
- KOD $9.00
- AVG Volume (30 Days)
- IONR 7.3K
- KOD 473.2K
- Earning Date
- IONR 01-01-0001
- KOD 05-23-2025
- Dividend Yield
- IONR N/A
- KOD N/A
- EPS Growth
- IONR N/A
- KOD N/A
- EPS
- IONR N/A
- KOD N/A
- Revenue
- IONR N/A
- KOD N/A
- Revenue This Year
- IONR N/A
- KOD N/A
- Revenue Next Year
- IONR N/A
- KOD N/A
- P/E Ratio
- IONR N/A
- KOD N/A
- Revenue Growth
- IONR N/A
- KOD N/A
- 52 Week Low
- IONR $3.02
- KOD $1.92
- 52 Week High
- IONR $9.35
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- IONR 51.41
- KOD 53.96
- Support Level
- IONR $3.33
- KOD $3.75
- Resistance Level
- IONR $3.77
- KOD $4.30
- Average True Range (ATR)
- IONR 0.18
- KOD 0.45
- MACD
- IONR 0.02
- KOD -0.02
- Stochastic Oscillator
- IONR 73.91
- KOD 23.43
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S.-based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.